Curaleaf (OTCMKTS:CURLF) Lifted to “Moderate Buy” at Cormark

Curaleaf (OTCMKTS:CURLF) was upgraded by equities researchers at Cormark from a “hold” rating to a “moderate buy” rating in a research report issued on Monday, Zacks.com reports. Cormark also issued estimates for Curaleaf’s FY2024 earnings at ($0.25) EPS and FY2025 earnings at ($0.18) EPS.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $6.25 price objective on shares of Curaleaf in a research report on Thursday, August 8th.

Curaleaf Trading Down 0.5 %

Shares of CURLF opened at $3.12 on Monday. The firm has a fifty day simple moving average of $3.97 and a two-hundred day simple moving average of $4.70. Curaleaf has a twelve month low of $2.51 and a twelve month high of $6.40. The stock has a market capitalization of $2.02 billion, a P/E ratio of -8.00 and a beta of 0.88. The company has a quick ratio of 0.36, a current ratio of 0.72 and a debt-to-equity ratio of 0.74.

Curaleaf (OTCMKTS:CURLF) last posted its earnings results on Wednesday, August 7th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Curaleaf had a negative return on equity of 14.43% and a negative net margin of 20.29%. The firm had revenue of $342.29 million for the quarter, compared to analysts’ expectations of $344.57 million. On average, research analysts anticipate that Curaleaf will post -0.21 EPS for the current year.

Curaleaf Company Profile

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.